- Home
- Products
- Customized ADCs
- EGFL7
- Anti-EGFL7 (Parsatuzumab)-MC-MMAF ADC
Anti-EGFL7 (Parsatuzumab)-MC-MMAF ADC (CAT#: ADC-W-1030)
This ADC product is comprised of an anti-EGFL7 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- EGFL7
- Alternative Names
- EGFL7; EGF-like-domain, multiple 7; epidermal growth factor-like protein 7; ZNEU1; EGF-like protein 7; NOTCH4-like protein; vascular endothelial statin; multiple EGF-like domains protein 7; multiple epidermal growth factor-like domains protein 7; NEU1; VE38 binds to DNA, causes DNA damag
- Target Entrez Gene ID
- 51162
- Target UniProt ID
- Q9UHF1
- Overview
- his gene encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. The encoded protein may play a role in regulating vasculogenesis. This protein may be involved in the growth and proliferation of tumor cells. Alternate splicing results in multiple transcript variants.
- Overview
- Humanized Anti-EGFL7 IgG1-kappa antibody, Parsatuzumab
- Generic name
- Parsatuzumab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1030. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1028 | Anti-EGFL7 (Parsatuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1033 | Anti-EGFL7 (Parsatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1032 | Anti-EGFL7 (Parsatuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1031 | Anti-EGFL7 (Parsatuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1029 | Anti-EGFL7 (Parsatuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-452 | Anti-CD70-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-518 | Anti-TM4SF1-Mc-LP2 ADC-2 | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-115 | Anti-CD33-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2561 | Anti-MSLN (Anetumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2550 | Anti-CD74-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2556 | Anti-CD79B (Polatuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2567 | Anti-MUC16 (Sofituzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CCR5 (PRO 140)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-769)
- Anti-Rabies Virus Glycoprotein (Foravirumab)-MC-MMAF ADC (CAT#: ADC-W-1966)
- Anti-IL6 (Enlimomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2249)
- Anti-MSLN (Amatuximab)-SPDB-DM4 ADC (CAT#: ADC-W-1593)
- Anti-EGFR (Zalutumumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2586)
- Anti-FUT4 (Fanolesomab)-SPDB-DM4 ADC (CAT#: ADC-W-2457)
- Anti-RhD (Atorolimumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1721)
- Anti-SLITRK6-MMAE ADC (CAT#: ADC-W-489)
- Anti-SELL (Aselizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1751)
- Anti-CSF1R (Emactuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2454)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
